SYBXOTCPharmaceutical PreparationsFiscal year ends December 31
SYNLOGIC, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.07+0.07 (+7.00%)
Close on Oct 19, 2026
- Market cap
- $13.29M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.2%
0M of 12M shares
Institutional holders
1
0 new, 1 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $284
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kryzanowski, John A. | 733,412 | 6.27% | 13G (passive) amendment | Dec 31, 2024 |
| Cable Car Capital, LP | 3,312,219 | 28.30% | 13D (active) amendment | Jul 28, 2026 |
| Ma-Weaver Jacob | 3,312,219 | 28.30% | 13D (active) amendment | Apr 2, 2026 |
| Nea 14 Gp, Ltd | 2,922,772 | 25.00% | 13D (active) amendment | Jul 28, 2026 |
| David Paolella | 1,140,000 | 9.70% | 13G (passive) | Jan 20, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SYBX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| DRW Securities, LLC | 23,763 | 0.19% | $16.66K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | 0M | 0.2% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2026 | 2 | 0M | 0.2% | 0 / 0 | 1 / 22 | 0M | 7M |
| Q4 2025 | 25 | 7M | 56.2% | 5 / 6 | 2 / 3 | 0M | 0M |
| Q3 2025 | 23 | 7M | 54.3% | 7 / 4 | 4 / 3 | 0M | 0M |
| Q2 2025 | 19 | 7M | 55.3% | 3 / 3 | 3 / 2 | 0M | 0M |
| Q1 2025 | 18 | 7M | 55.4% | 1 / 3 | 3 / 0 | 0M | 0M |
| Q4 2024 | 18 | 7M | 55.2% | 2 / 1 | 3 / 1 | 0M | 0M |
| Q3 2024 | 17 | 7M | 55.7% | 2 / 1 | 4 / 1 | 0M | 0M |
| Q2 2024 | 17 | 7M | 56.7% | 2 / 2 | 4 / 2 | 0M | 0M |
| Q1 2024 | 17 | 7M | 56.6% | 2 / 5 | 4 / 9 | 3M | 1M |
| Q4 2023 | 24 | 5M | 38.5% | 5 / 9 | 5 / 7 | 3M | 1M |
| Q3 2023 | 27 | 3M | 21.7% | 27 / 0 | 0 / 0 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SYBX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Large-Cap Growth Portfolio | 5,323 | 0.04% | $3.73K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mary Beth Dooley | See Remarks below | 12,744 | 0.10% | Oct 31, 2025 |
| Mohamad Makhzoumi | Director, 10% owner | – | – | Aug 14, 2026 |
| Scott D. Sandell | Director, 10% owner | 7,151,713 | 58.39% | Aug 14, 2026 |
| Anthony A. Florence Jr. | Director, 10% owner | 4,228,940 | 34.52% | Aug 14, 2026 |
| New Enterprise Associates 14, L.P. | Director, 10% owner | 2,114,375 | 17.26% | Aug 14, 2026 |
| NEA Partners 14, L.P. | Director, 10% owner | – | – | Aug 14, 2026 |
| Nea 14 Gp, Ltd | Director, 10% owner | 4,228,940 | 34.52% | Aug 14, 2026 |
| James P. Flynn | Director | 15,000 | 0.12% | Apr 29, 2025 |
| Richard P. Shea | Director | 15,506 | 0.13% | Apr 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mary Beth Dooley See Remarks below | Oct 29, 2025 | Sale | −157 | $1.81 | $284 | 12,744 |
| James P. Flynn Director | Apr 26, 2025 | Award | +15,000 | – | – | 15,000 |
| Richard P. Shea Director | Apr 26, 2025 | Award | +15,000 | – | – | 15,506 |
| Mary Beth Dooley See Remarks below | Apr 2, 2025 | Sale | −144 | $1.20 | $173 | 12,901 |
| Mary Beth Dooley See Remarks below | Feb 3, 2025 | Sale | −2,107 | $1.33 | $2.80K | 13,045 |
| Mary Beth Dooley Head of Finance | Oct 29, 2024 | Sale | −79 | $1.40 | $111 | 15,152 |
| Mary Beth Dooley Head of Finance | Apr 2, 2024 | Sale | −188 | $1.73 | $325 | 15,231 |
| Antoine Awad Chief Operating Officer | Apr 2, 2024 | Sale | −372 | $1.73 | $644 | 33,859 |
| Aoife Brennan See Remarks, Director | Apr 3, 2023 | Sale(10b5-1 plan) | −19,042 | $0.58 | $11.04K | 256,301 |
| Antoine Awad Chief Operating Officer | Apr 3, 2023 | Sale | −6,438 | $0.58 | $3.73K | 74,732 |
| Michael Vangsted Jensen Chief Financial Officer | Apr 3, 2023 | Sale | −2,553 | $0.58 | $1.48K | 46,947 |
| Michael Vangsted Jensen Chief Financial Officer | May 24, 2022 | Buy | +9,500 | $1.12 | $10.64K | 39,500 |
| Aoife Brennan See Remarks, Director | Apr 4, 2022 | Sale(10b5-1 plan) | −8,894 | $2.45 | $21.79K | 275,343 |
| Antoine Awad Chief Operating Officer | Apr 4, 2022 | Sale(10b5-1 plan) | −2,650 | $2.45 | $6.49K | 81,170 |
| Michael Vangsted Jensen Chief Financial Officer | Mar 3, 2022 | Award | +30,000 | – | – | 30,000 |
| Aoife Brennan See Remarks, Director | Feb 4, 2022 | Award | +106,920 | – | – | 284,237 |
| Antoine Awad Chief Operating Officer | Feb 4, 2022 | Award | +40,820 | – | – | 83,820 |
| Chau Quang Khuong Director | Apr 20, 2021 | Award | +1,666,666 | $3.00 | $5.00M | 3,696,662 |
| Capital GP VI LLC OrbiMed Director | Apr 20, 2021 | Award | +1,666,666 | $3.00 | $5.00M | 3,696,662 |
| Antoine Awad Chief Operating Officer | Mar 10, 2021 | Award | +17,500 | – | – | 43,000 |
| Richard J. Riese Chief Medical Officer | Mar 10, 2021 | Award | +17,500 | – | – | 39,000 |
| Aoife Brennan See Remarks, Director | Mar 10, 2021 | Award | +71,250 | – | – | 177,317 |
| Aoife Brennan See Remarks, Director | Mar 10, 2020 | Award | +46,300 | – | – | 106,067 |
| Richard J. Riese Chief Medical Officer | Mar 10, 2020 | Award | +13,500 | – | – | 21,500 |
| Richard P. Shea Director | Dec 13, 2019 | Buy | +7,500 | $2.74 | $20.55K | 7,500 |
| Richard J. Riese Chief Medical Officer | Sep 23, 2019 | Award | +8,000 | – | – | 8,000 |
| Scott Eric Plevy Chief Scientific Officer | Sep 23, 2019 | Award | +8,000 | – | – | 8,000 |
| Aoife Brennan See Remarks, Director | Sep 23, 2019 | Award | +8,000 | – | – | 59,767 |
| Paul Francis Miller Chief Scientific Officer | Feb 13, 2019 | Sale(10b5-1 plan) | −5,849 | $9.75 | $57.03K | 48,135 |
| Paul Francis Miller Chief Scientific Officer | Feb 12, 2019 | Sale(10b5-1 plan) | −3,151 | $9.75 | $30.72K | 53,984 |
| Paul Francis Miller Chief Scientific Officer | Oct 18, 2018 | Sale(10b5-1 plan) | −3,000 | $9.77 | $29.31K | 57,135 |
| Paul Francis Miller Chief Scientific Officer | Sep 18, 2018 | Sale(10b5-1 plan) | −3,000 | $13.05 | $39.15K | 60,135 |
| Paul Francis Miller Chief Scientific Officer | Sep 5, 2018 | Sale(10b5-1 plan) | −3,000 | $12.55 | $37.65K | 63,135 |
| Paul Francis Miller Chief Scientific Officer | Aug 30, 2018 | Sale(10b5-1 plan) | −1,342 | $9.76 | $13.10K | 66,135 |
| Paul Francis Miller Chief Scientific Officer | Aug 29, 2018 | Sale(10b5-1 plan) | −1,658 | $9.77 | $16.20K | 67,477 |
| Paul Francis Miller Chief Scientific Officer | Jul 18, 2018 | Sale(10b5-1 plan) | −3,000 | $11.01 | $33.03K | 69,135 |
| Paul Francis Miller Chief Scientific Officer | Jun 20, 2018 | Sale(10b5-1 plan) | −1,054 | $9.80 | $10.33K | 72,135 |
| Paul Francis Miller Chief Scientific Officer | Jun 20, 2018 | Sale(10b5-1 plan) | −1,000 | $9.75 | $9.75K | 72,135 |
| Paul Francis Miller Chief Scientific Officer | Jun 19, 2018 | Sale(10b5-1 plan) | −946 | $9.75 | $9.22K | 74,189 |
| Capital GP VI LLC OrbiMed Director | Jan 26, 2018 | Award | +715,000 | $9.75 | $6.97M | 2,029,996 |
| Michael Powell Director | Jan 26, 2018 | Award | +150,000 | $9.75 | $1.46M | 574,972 |
| Chau Quang Khuong Director | Jan 26, 2018 | Award | +715,000 | $9.75 | $6.97M | 2,029,996 |
| Nea 14 Gp, Ltd 10% owner | Jan 26, 2018 | Award | +410,000 | $9.75 | $4.00M | 4,228,940 |
| Patrick J. Kerins 10% owner | Jan 26, 2018 | Award | +410,000 | $9.75 | $4.00M | 4,228,940 |
| Peter W. Sonsini 10% owner | Jan 26, 2018 | Award | +410,000 | $9.75 | $4.00M | 4,228,940 |
| David M. Mott 10% owner | Jan 26, 2018 | Award | +410,000 | $9.75 | $4.00M | 4,228,940 |
| Peter J. Barris 10% owner | Jan 26, 2018 | Award | +410,000 | $9.75 | $4.00M | 4,228,940 |
| Ravi Viswanathan 10% owner | Jan 26, 2018 | Award | +410,000 | $9.75 | $4.00M | 4,228,940 |
| M. James Barrett 10% owner | Jan 26, 2018 | Award | +410,000 | $9.75 | $4.00M | 4,228,940 |
| Anthony A. Florence Jr. 10% owner | Jan 26, 2018 | Award | +410,000 | $9.75 | $4.00M | 4,228,940 |
| Scott D. Sandell 10% owner | Jan 26, 2018 | Award | +410,000 | $9.75 | $4.00M | 4,228,940 |
| Forest Baskett 10% owner | Jan 26, 2018 | Award | +410,000 | $9.75 | $4.00M | 4,228,940 |
| Jose-Carlos Gutierrez-Ramos See Remarks, Director | Oct 2, 2017 | Gift | −10,000 | – | – | 352,619 |
| Peter J. Barris 10% owner | Aug 28, 2017 | Award | +3,394,439 | – | – | 3,818,940 |
| M. James Barrett 10% owner | Aug 28, 2017 | Award | +3,394,439 | – | – | 3,818,940 |
| Ravi Viswanathan 10% owner | Aug 28, 2017 | Award | +3,394,439 | – | – | 3,818,940 |
| Patrick J. Kerins 10% owner | Aug 28, 2017 | Award | +3,394,439 | – | – | 3,818,940 |
| Forest Baskett 10% owner | Aug 28, 2017 | Award | +3,394,439 | – | – | 3,818,940 |
| Scott D. Sandell 10% owner | Aug 28, 2017 | Award | +3,394,439 | – | – | 3,818,940 |
| Anthony A. Florence Jr. 10% owner | Aug 28, 2017 | Award | +3,394,439 | – | – | 3,818,940 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Aoife Brennan Affiliate | Apr 22, 2024 | 88,293 | $161.58K | Apr 19, 2024 | Options |
| Aoife Brennan Affiliate | Mar 21, 2024 | 6,868 | $11.88K | Mar 21, 2024 | Owned Shares |